Form 8-K - Current report:
SEC Accession No. 0000950170-25-106228
Filing Date
2025-08-11
Accepted
2025-08-11 07:15:29
Documents
12
Period of Report
2025-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apge-20250811.htm   iXBRL 8-K 49483
2 EX-99.1 apge-ex99_1.htm EX-99.1 241381
3 GRAPHIC img126220792_0.jpg GRAPHIC 79141
  Complete submission text file 0000950170-25-106228.txt   518901

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20250811.xsd EX-101.SCH 23918
14 EXTRACTED XBRL INSTANCE DOCUMENT apge-20250811_htm.xml XML 4546
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)